MedTrace Logo

Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

NCT02536664 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 505

Last updated 2023-04-18

Study results available
· View outcomes & findings →

Summary

It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.

Conditions

Interventions

DRUG

Rituximab

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02536664 on ClinicalTrials.gov